Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 2

Sponsor Class

OTHER 9NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Hematologic Neoplasms 2Leukemia, Myeloid, Acute 1Bronchiolitis Obliterans Syndrome 1

Interventions

Specimen Handling 200Magnetic Resonance Spectroscopy 151Biopsy 113Nivolumab 40Immunoglobulin G 40Disulfides 40Cisplatin 38Cyclophosphamide 37Platinum 36Paclitaxel 361,2-diaminocyclohexaneplatinum II citrate 36Carboplatin 35Taxes 34Radiation 34X-Rays 29Radiotherapy 28pembrolizumab 27Doxorubicin 25Bevacizumab 24olaparib 22atezolizumab 22Gemcitabine 22Vincristine 19Prednisone 19fludarabine 18Ipilimumab 18CTLA-4 Antigen 18venetoclax 17durvalumab 17Phantoms, Imaging 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Mesna × 30 days × Clear all
NCT04959175 2026-06-11

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
320 enrolled
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

NCT05436418 2026-06-11

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
260 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡